Bristol Myers Squibb - Bristol Myers Squibb和Novartis是两家值得长期投资的医药公司[1] - Bristol Myers虽然面临一些问题，但仍然保持着股息计划，并在过去五年内将股息增加了46%[3] Novartis - Novartis在过去一年的财务表现相当稳健，去年净销售额同比增长8%至454亿美元[9] - Novartis已连续27年增加股息，目前提供4.04%的股息收益率[13]

Bristol Myers Squibb (BMY) ended the recent trading session at $48.51, demonstrating a +0.48% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 1.2%. Meanwhile, the Dow experienced a drop of 0.65%, and the technology-dominated Nasdaq saw a decrease of 1.79%.The the stock of biopharmaceutical company has fallen by 7.76% in the past month, lagging the Medical sector's loss of 6.57% and the S&P 500's loss of 0.85%.Analysts and investors alike will be ...

6 Ultimate Dividend Stocks for Long-Term Passive Income Growth relif / Getty Images Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciations have contributed 68%. Therefore, sustainable dividend income and capital appreciation potential are essential for total return expectations.A recent study from the Hartford Funds, in collaboration with Ned Davis Research, revealed that dividend stocks have consistently outperformed non-payers. Over the ...

公司业绩 - 公司预计2024年营收将同比增长个位数百分比，每股摊薄收益范围为7.1至7.4美元，非GAAP P/E [FWD]约为7倍，显示公司不仅在行业内，还在关键竞争对手如辉瑞公司、诺华公司和默克公司之下交易[3] - 公司在2023年第四季度的总销售额为3.2亿美元，同比增长60.8%，需求增长率季度内急剧上升，主要是由于FDA批准Reblozyl用于治疗某些低风险和中风险骨髓增生异常综合征患者的贫血，以及欧洲和日本的强劲需求[5] - 根据Reblozyl历史销售增长率、未来三年的预期标签扩展以及发布支持其在贫血治疗中的竞争优势的额外数据，预计其总销售额将在2027年达到44.6亿美元[7] - 预计公司2025年的非GAAP每股收益将达到7.06美元，P/E比率为7.12倍，对于寻求在医疗保健领域寻找被低估资产的保守投资者来说，这是一个有吸引力的价值[9] 产品研发 - Reblozyl是一种重组融合蛋白，用于治疗某些β-地中海贫血患者，通过结合TGF-β超家族配体发挥作用，最终导致Smad2/3信号的减少以及成熟红细胞数量的增加，主要负责将氧气输送到身体组织[4] - EMA于2024年4月2日批准布里斯托尔迈尔斯斯奎布公司的产品作为某些MDS患者的贫血一线治疗，根据关键临床试验结果，证明其良好的安全性以及Reblozyl相对于epoetin alfa的优越疗效[6] - 公司在2024年4月6日发布了来自EMERGENT-4研究的额外结果，该研究评估了KarXT（xanomeline-trospium）用于治疗精神分裂症患者的疗效，结果显示在接受公司实验药物的患者中，各种代谢参数的改善和良好的安全性，以及相对于接受安慰剂的患者群体的精神分裂症症状显著改善[8] 业务战略 - 公司CEO推广的业务战略开始见效，包括针对巨大医疗需求的产品候选品管道的相对高速发展，稳定Abraxane的销售以及通过收购开发下一代治疗药物的制药公司来减少由于Eliquis、Opdivo在未来五年失去独家权带来的财务风险[10] - 公司获得了几种药物的监管批准，这些药物在治疗各种癌症类型方面具有竞争优势，此外，公司极高的股息率和管理层积极利用股票回购计划的投资论点使布里斯托尔迈尔斯斯奎布公司成为金融市场参与者的有吸引力资产[11]

Biotech stocks are one of the hottest investing opportunities in the stock marketlately.The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF’s (NYSEARCA:XBI) 25% bump in value over the past six months, outpacing broader market gains. Moreover, with the impending interest rates cuts, it might be an ideal time to scoop the top biotech players on the dip.Interest in the biotech sphere will continue to grow on the back of several factors, including revolutionary new treatments, an aging p ...

股价表现 - Bristol Myers Squibb (BMY) 最近的股价为 $51.60，较前一个交易日上涨了 +0.98% [1] - 过去一个月，这家生物制药公司的股价下跌了 6%，落后于医疗行业的下跌幅度为 4.03% 和标普500指数的上涨幅度为 1.65% [2] 财报预测 - 分析师和投资者将密切关注 Bristol Myers Squibb 即将公布的财报。公司的盈利报告将于 2024 年 4 月 25 日公开，预计每股收益为 $1.52，较去年同期下降了 25.85%，预计营收为 $11.46 亿美元，较去年同期增长了 1.11% [3] - 根据 Zacks Consensus Estimates，预计 Bristol Myers Squibb 年度盈利为每股 $6.63，营收为 $461.2 亿美元，较去年分别下降了 11.72% 和增长了 2.49% [4] 估值和评级 - 近期分析师对 Bristol Myers Squibb 的估值进行了调整，这反映了最新的短期业务趋势，正面的估值调整可视为公司业务前景的良好迹象 [5] - 研究表明，这些估值变化与即将到来的股价表现有直接关系，公司开发了 Zacks Rank 模型，该模型考虑了这些估值变化并提供了可操作的评级系统 [6] - Zacks Rank 系统从 1（强热门）到 5（强卖出），自 1988 年以来，1 股票的平均年回报率为 +25%，最近 30 天，Zacks Consensus EPS 估计增长了 0.42%，目前 Bristol Myers Squibb 的 Zacks Rank 为 3（持有） [7] 行业比较 - 就估值而言，Bristol Myers Squibb 目前的前瞻市盈率为 7.7，相对于行业平均前瞻市盈率 23.81，表示折价交易 [8] - 投资者还应注意，BMY 目前的 PEG 比率为 1.54，PEG 比率类似于常用的市盈率，但该参数还包括公司预期的盈利增长轨迹，BMY 所在行业昨日收盘时的平均 PEG 比率为 1.84 [9] 行业排名 - 医疗 - 生物医学和遗传学行业属于医疗行业，该行业目前的 Zacks Industry Rank 为 83，位于所有 250+ 行业的前 33% [10] - Zacks Industry Rank 通过测量各个行业组内个别股票的平均 Zacks Rank 来衡量我们各个行业组的实力，研究显示，评级排名前 50% 的行业的表现超过后 50% 的行业表现约 2 倍 [11] 提醒 - 请务必使用 Zacks.com 监控所有这些影响股价的指标，以及在未来的交易日内持续关注 [12]

In this articleBMYJNJJonathan Raa | Nurphoto | Getty ImagesThink a friend or colleague should be getting this newsletter? Share this link with them to sign up.Hi folks! Two competing cell therapies from Bristol Myers Squibb and Johnson & Johnson both got good news from the Food and Drug Administration on Friday. But J&J's drug is walking away with a notable edge over its rival.The FDA expanded the approvals of both therapies, allowing patients to use them as earlier lines of treatment for a type of blood ca ...

Bristol Myers Squibb (BMY) announced data from the cohorts of the KRYSTAL-1 study, evaluating the lung cancer drug Krazati (adagrasib) in combination with Erbitux (cetuximab), for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC).KRYSTAL-1 is an open-label, multicenter, multiple expansion cohort phase I/II study to determine the safety and efficacy of Krazati in patients with advanced solid tumors that harbor a KRASG12C mutation.The pri ...

Bristol Myers Squibb (BMY) announced that the FDA approved a label expansion for chimeric antigen receptor (CAR) T cell immunotherapy Abecma. The therapy is now approved for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.It is to be noted that Abecma is being jointly developed and commercialized in the United States by Bristol My ...

April 6 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics.The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. Long-term data of the drug reinforced the findings that were seen in previous short-term studies, the company sa ...